Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avacta Group plc ( (GB:AVCT) ) has shared an update.
Avacta Group plc has announced a delay in the publication of its preliminary results for the year ended December 31, 2024, now scheduled for June 4, 2025, due to pending audit work related to the disposal of Launch Diagnostics. Despite the delay, Avacta assures stakeholders that there is no impact on its financial position or cash runway. The company will hold a live presentation for shareholders on the same day, providing an opportunity for investors to engage with the management team.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing next-generation peptide drug conjugates (PDC) targeting anti-tumor payloads directly to tumors. The company utilizes its proprietary pre|CISION® platform, which leverages a tumor-specific protease to deliver potent cancer therapies while minimizing damage to healthy tissues.
Average Trading Volume: 1,921,572
Technical Sentiment Signal: Sell
Current Market Cap: £106.3M
For detailed information about AVCT stock, go to TipRanks’ Stock Analysis page.